Full Breakdown
Pentagon Temporarily Rescinds Testosterone Screening Guidance
9/4/2026, 12:29:43 AM
Core Event
By the following day the document and its accompanying statement had been removed from the Defense Department website. As of September 3, the interim guidance continued to govern screenings.
Background & Context
The policy created separate pathways for men and women: men 30 and older would receive a questionnaire that could trigger a blood test and, if indicated, testosterone-replacement therapy; women would be screened for fatigue, menstrual disruption or relative-energy-deficiency-in-sport (RED-S) symptoms, with off-label testosterone considered only for post-menopausal women with markedly low sexual desire.
Data & Statistics
- Mandatory blood tests apply to all male service members 30 and older; men under 30 may request testing or be screened when clinicians identify warning signs.
- Women are not required to undergo routine testosterone testing; they are asked about hormonal-dysregulation symptoms and referred for further assessment as needed.
- The American Urological Association and the Endocrine Society do not recommend routine low-testosterone screening.
- Derek Griffith of the University of Pennsylvania noted that only ? 2 % of the male population has clinically low testosterone, suggesting the issue is not a major problem for the force.
- The U.S. Food and Drug Administration announced a meeting of experts in mid-September to discuss the medical use of testosterone.
Official Statements & Responses
- A Pentagon spokesperson said the guidance was removed “to allow for updates” and that the interim guidance “remains in effect” while the final document is prepared.
- Pentagon spokesman Sean Parnell emphasized that “we demand candid military advice” and defended the department’s handling of the guidance, characterizing criticism as “inaccurate” and a “betrayal of the force.”
Criticism & Opposition
- **Dr.
- Dr. Jason Goldman, former president of the American College of Physicians, called the policy “bad policy all around,” noting that testosterone replacement can worsen sleep apnea, increase red-cell counts, raise heart-disease risk, impair fertility and exacerbate undiagnosed prostate cancer.
- Both the American Urological Association and the Endocrine Society have stated that routine screening for low testosterone lacks supporting evidence and is not part of their clinical guidelines.
Conflicting Reports & Gaps
- The Pentagon’s rationale for the rapid removal of the guidance remains vague; officials cited “updates” but did not specify which sections required revision.
- The FDA’s upcoming expert meeting indicates that regulatory clarification is still pending, leaving the final policy’s content and implementation timeline uncertain.
Verbatim Quotes
- “We owe our warriors the absolute best medical care in the world, and this program delivers on that obligation,” — Pete Hegseth, put defense secretary
- “When someone has a real, clinically diagnosed testosterone deficiency, treatment can be meaningful,” — Dr. Demetre Daskalakis
- “Taking testosterone is not going to make you more manly, more strong, or a more robust individual. That's just not how it works,” — Dr. Jason Goldman
- “Of course, we demand candid military advice,” — Sean Parnell, statement from spokesperson
